Echistatin/BYL-719 impedes epithelial-mesenchymal transition in pulmonary fibrosis induced by silica through modulation of the Integrin β1/ILK/PI3K signaling pathway
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112368 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Haibin Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, North China University of Science and Technology, Tangshan 063000, China; School of Public Health, Xinxiang Medical Universi…. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Signal Transduction, Integrin beta1, Pulmonary Fibrosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: North China University of Science and Technology.
Abstract (Originalsprache)
Silicosis is a chronic fibroproliferative lung disease caused by long-term inhalation of crystalline silica dust, characterized by the proliferation of fibroblasts and pulmonary interstitial fibrosis. Currently, there are no effective treatments available. Recent research suggests that the Integrin β1/ILK/PI3K signaling pathway may be associated with the pathogenesis of silicosis fibrosis. In this study, we investigated the effects of Echistatin (Integrin β1 inhibitor) and BYL-719 (PI3K inhibitor) on silicosis rats at 28 and 56 days after silica exposure. Histopathological analysis of rat lung tissue was performed using H&E staining and Masson staining. Immunohistochemistry, Western blotting, and qRT-PCR were employed to assess the expression of markers associated with epithelial-mesenchymal transition (EMT), fibrosis, and the Integrin β1/ILK/PI3K pathway in lung tissue. The results showed that Echistatin, BYL 719 or their combination up-regulated the expression of E-cadherin and down-regulated the expression of Vimentin and extracellular matrix (ECM) components, including type I and type III collagen. The increase of Snail, AKT and β-catenin in the downstream Integrin β1/ILK/PI3K pathway was inhibited. These results indicate that Echistatin and BYL 719 can inhibit EMT and pulmonary fibrosis by blocking different stages of Integrinβ1 /ILK/PI3K signaling pathway. This indicates that the Integrin β1/ILK/PI3K signaling pathway is associated with silica-induced EMT and may serve as a potential therapeutic target for silicosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, North China University of Science and Technology, Tangshan 063000, China; School of Public Health, Xinxiang Medical University, Xinxiang 453003, China.
- School of Public Health, Xinxiang Medical University, Xinxiang 453003, China.
- School of Public Health, North China University of Science and Technology, Tangshan 063000, China.
- School of Public Health, North China University of Science and Technology, Tangshan 063000, China; School of Public Health, Xinxiang Medical University, Xinxiang 453003, China. Electronic address: sanqiaoyao@126.com.
Förderung
- North China University of Science and Technology
Zitieren
APA
Li, H., Wang, P., Hu, M., Xu, S., Li, X., Xu, D., Feng, K., Zhou, Q., Chang, M., & Yao, S. (2024). Echistatin/BYL-719 impedes epithelial-mesenchymal transition in pulmonary fibrosis induced by silica through modulation of the Integrin β1/ILK/PI3K signaling pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112368
Vancouver
Li H, Wang P, Hu M, Xu S, Li X, Xu D, et al. Echistatin/BYL-719 impedes epithelial-mesenchymal transition in pulmonary fibrosis induced by silica through modulation of the Integrin β1/ILK/PI3K signaling pathway. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112368
BibTeX
@article{Li2024,
author = {Li, Haibin and Wang, Penghao and Hu, Meng and Xu, Shushuo and Li, Xinxiao and Xu, Deliang and Feng, Kaihao and Zhou, Qiang and Chang, Meiyu and Yao, Sanqiao},
title = {Echistatin/BYL-719 impedes epithelial-mesenchymal transition in pulmonary fibrosis induced by silica through modulation of the Integrin β1/ILK/PI3K signaling pathway},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112368}
}
EUVIMED